Somatic mutations of the HER2 in metastatic breast cancer
- 19 October 2014
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (12) , 11851-11854
Abstract
Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the full length of HER2 in 198 metastatic breast cancers (MBC) as well as 34 other epithelial cancers (bladder, prostate, and colorectal cancers) and compared the mutational status with clinic pathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 11.6 % (23 of 198) of MBC and were absent in other types of cancers. HER2 mutations were located in exon 15 and the in-frame insertions in exon 20 with corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in patient after the administration of trastuzumab (34.8 %, 8 of 23; P = 0.02). Mutations in exon 15 and 20 were more potent than wild-type HER2 in associating with activating signal transducers and inducing survival, invasiveness, and tumorigenicity.Keywords
This publication has 18 references indexed in Scilit:
- Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signalingProceedings of the National Academy of Sciences, 2012
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Signaling through ERBB receptors: Multiple layers of diversity and controlCellular Signalling, 2006
- Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancerNature Clinical Practice Oncology, 2006
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005
- Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?Trends in Molecular Medicine, 2004
- Intragenic ERBB2 kinase mutations in tumoursNature, 2004
- Switching on kinases: oncogenic activation of BRAF and the PDGFR familyNature Reviews Cancer, 2004
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987